Matthew P. Young Sells 1,152 Shares of Jazz Pharmaceuticals PLC (JAZZ) Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CFO Matthew P. Young sold 1,152 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $135.41, for a total transaction of $155,992.32. Following the sale, the chief financial officer now directly owns 38,700 shares in the company, valued at $5,240,367. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Matthew P. Young also recently made the following trade(s):

Get Jazz Pharmaceuticals alerts: On Wednesday, February 27th, Matthew P. Young sold 1,916 shares of Jazz Pharmaceuticals stock. The shares were sold at an average price of $131.46, for a total transaction of $251,877.36.

Shares of Jazz Pharmaceuticals stock traded up $0.18 on Thursday, hitting $135.88. 939,995 shares of the company traded hands, compared to its average volume of 544,635. The company has a quick ratio of 4.16, a current ratio of 4.29 and a debt-to-equity ratio of 0.52. Jazz Pharmaceuticals PLC has a 12-month low of $113.52 and a 12-month high of $184.00. The stock has a market cap of $7.60 billion, a P/E ratio of 10.91, a P/E/G ratio of 0.88 and a beta of 1.17.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, February 26th. The specialty pharmaceutical company reported $3.64 EPS for the quarter, beating the consensus estimate of $2.66 by $0.98. Jazz Pharmaceuticals had a net margin of 28.09% and a return on equity of 24.92%. The business had revenue of $476.46 million for the quarter, compared to analysts’ expectations of $459.48 million. During the same period in the previous year, the company posted $2.95 EPS. Jazz Pharmaceuticals’s revenue was up 9.2% on a year-over-year basis. On average, equities research analysts expect that Jazz Pharmaceuticals PLC will post 13.35 earnings per share for the current fiscal year.

JAZZ has been the topic of several recent analyst reports. Oppenheimer set a $180.00 target price on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, December 23rd. BidaskClub raised shares of Jazz Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, December 18th. Wells Fargo & Co reissued a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Sunday, December 23rd. Wolfe Research initiated coverage on shares of Jazz Pharmaceuticals in a research note on Friday, December 14th. They set a “peer perform” rating on the stock. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $185.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday, February 12th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the company. Jazz Pharmaceuticals has an average rating of “Buy” and a consensus target price of $190.63.

Institutional investors have recently bought and sold shares of the company. Aperio Group LLC boosted its holdings in Jazz Pharmaceuticals by 5.3% in the third quarter. Aperio Group LLC now owns 11,656 shares of the specialty pharmaceutical company’s stock worth $1,960,000 after purchasing an additional 587 shares in the last quarter. First Trust Advisors LP boosted its holdings in Jazz Pharmaceuticals by 412.4% in the third quarter. First Trust Advisors LP now owns 116,482 shares of the specialty pharmaceutical company’s stock worth $19,584,000 after purchasing an additional 93,748 shares in the last quarter. Robeco Institutional Asset Management B.V. boosted its holdings in Jazz Pharmaceuticals by 143.4% in the third quarter. Robeco Institutional Asset Management B.V. now owns 22,468 shares of the specialty pharmaceutical company’s stock worth $3,776,000 after purchasing an additional 13,237 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its holdings in Jazz Pharmaceuticals by 28.8% in the third quarter. State Board of Administration of Florida Retirement System now owns 58,523 shares of the specialty pharmaceutical company’s stock worth $9,839,000 after purchasing an additional 13,076 shares in the last quarter. Finally, US Bancorp DE boosted its holdings in Jazz Pharmaceuticals by 33.7% in the third quarter. US Bancorp DE now owns 15,646 shares of the specialty pharmaceutical company’s stock worth $2,631,000 after purchasing an additional 3,946 shares in the last quarter. Institutional investors and hedge funds own 91.97% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Matthew P. Young Sells 1,152 Shares of Jazz Pharmaceuticals PLC (JAZZ) Stock” was first reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/4204759/matthew-p-young-sells-1152-shares-of-jazz-pharmaceuticals-plc-jazz-stock.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Read More: How is net asset value different from market price?